enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada. Show more

Location: 4868 Rue Levy, Montreal, QC, H4R 2P1, Canada | Website: https://www.engene.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

248.9M

52 Wk Range

$2.65 - $11.00

Previous Close

$4.87

Open

$5.00

Volume

2,094,499

Day Range

$4.63 - $5.03

Enterprise Value

61.45M

Cash

217.4M

Avg Qtr Burn

-18.85M

Insider Ownership

13.63%

Institutional Own.

89.73%

Qtr Updated

04/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Detalimogene (EG-70) Details Non-Muscle Invasive Bladder Cancer (NMIBC)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.